# Ozempic Click/Dose Research Tracker

Living source log for reporting on Ozempic pen click-counting, dose-splitting, medication errors, and online/viral practices.

Last updated: 2026-07-14

## How to use this file

- Add new sources here before summarizing them in the findings memo.
- Search the source title, URL, and tags before beginning another run.
- Treat each pen configuration as a separate research object; “2 mg pen” can mean total drug in the cartridge, while “2 mg dose pen” means the marked delivered dose.
- Keep official regulatory documents, clinical/health-system guidance, journalism, and user-generated material in separate evidence tiers.

## Evidence tiers

- **A — Primary/regulatory:** FDA label, DailyMed, Novo medical-information response, official instructions.
- **B — Clinical/professional:** hospital/clinic handouts, poison-control case series, medication-safety organizations.
- **C — Reported practice:** reputable journalism quoting clinicians/patients.
- **D — Online/viral:** Reddit, calculators, affiliate/telehealth SEO pages, social posts. Useful for mapping the phenomenon; not validation.

## Source log

| ID | Source | Tier | Lane | Checked | Key contribution | Reuse / overlap note |
|---|---|---:|---|---|---|---|
| A1 | [FDA Ozempic prescribing information, revised June 2026](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf) | A | Product/device | 2026-07-14 | U.S. configurations: 2 mg/3 mL delivers 0.25/0.5 mg; 4 mg/3 mL delivers 1 mg; 8 mg/3 mL delivers 2 mg. Labels say use dose counter and do not count clicks. | Core source; update if FDA revises label. |
| A2 | [DailyMed Ozempic record](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79) | A | Product/device | 2026-07-14 | Current consumer-facing instructions; 4 mg/3 mL pen delivers 1 mg increments only; 8 mg/3 mL delivers 2 mg increments only. | Cross-check against A1 after any label change. |
| A3 | [Novo Nordisk medical-information response: dosing by number of clicks](https://www.adea.com.au/wp-content/uploads/2024/03/OZEMPIC-semaglutide-and-Pen-Dosing-by-Clicks.pdf) | A | Manufacturer position | 2026-07-14 | Novo says it has not evaluated click dosing, cannot guarantee dose/volume per click, and does not recommend unmarked doses. | Most direct source for “Novo said don’t do it.” |
| A4 | [Ozempic official dosing/use page](https://www.ozempic.com/ozempic-pen/dosing.html) | A | Product/device | 2026-07-14 | Official instructions identify red/blue/yellow U.S. pen dose markings and reinforce use of the dose counter. | Patient-facing companion to A1/A2. |
| A5 | [Novo Nordisk Canada Ozempic product monograph, authorized November 2025](https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/ozempic/product-monograph/ozempic-en-pm-04-november-2025.pdf) | A | Product/device / market variants | 2026-07-14 | Lists six Canadian pen variants, including two 4-mg-total pens with different marked doses and two 8-mg-total pens with different marked doses. Says forward/backward clicks differ, not to count clicks, to hold six seconds, and to discard after 8 weeks. | Establishes that total mg/volume does not uniquely identify the device outside the current U.S. configuration. |
| A6 | [EMA Ozempic product information, updated July 2026](https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf) | A | Product/device / dose volume | 2026-07-14 | Lists 4 mg/3 mL presentations delivering either 0.5 mg in 0.37 mL or 1 mg in 0.74 mL, and 8 mg/3 mL presentations delivering either 1 mg in 0.37 mL or 2 mg in 0.74 mL. | Useful for rounded volume/concentration arithmetic; do not assume European presentations are identical to U.S. devices. |
| B1 | [BC Children’s Hospital Endocrinology & Diabetes Unit: Semaglutide Click-Counting](https://ubccpd.ca/sites/default/files/documents/semaclick.pdf) | B | Clinical practice | 2026-07-14 | Explicitly describes click-counting; calls doses approximate, off-label, not manufacturer-recommended, but widely adopted. Lists 18 ≈ 0.25 mg, 36 ≈ 0.5 mg, 72 ≈ 1 mg. It also says “1 click = 0.01 mg,” which is incompatible with 72 clicks = 1 mg. | Strong practice evidence but not mathematically self-consistent; treat the 0.01-mg line as an unresolved likely unit typo. |
| B2 | [ISMP Canada: newer diabetes medication incidents](https://ismpcanada.ca/bulletin/newer-classes-of-medications-for-diabetes-treatment-a-multi-incident-analysis-of-reports-from-the-community-pharmacy-setting/) | B | Medication safety | 2026-07-14 | Highlights multiple semaglutide pen strengths/dose-delivery options as a pharmacy-error risk; recommends independent double-checks and patient counseling. | Supports “the device ecosystem is confusing” angle. |
| B3 | [FDA warning on compounded semaglutide dosing errors](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded) | A/B | Medication errors | 2026-07-14 | Reports incorrect measurement, concentration confusion, 5–20× errors, severe GI symptoms, dehydration, pancreatitis, gallstones, and hospital care. | Mostly compounded-vial evidence; use as adjacent risk evidence, not proof of Ozempic click errors. |
| B4 | [Lambson et al., poison-control case series](https://www.sciencedirect.com/science/article/abs/pii/S1544319123002315) | B | Medication errors | 2026-07-14 | Three cases involving compounded semaglutide; two had 10× errors, all had nausea/vomiting/abdominal pain, one received IV fluids. | Published clinical evidence; distinguish compounded product from branded pen. |
| B5 | [PubMed: semaglutide overdose administration-error case series](https://pubmed.ncbi.nlm.nih.gov/38470137/) | B | Medication errors | 2026-07-14 | Independent case-series record focused on initiation/education and overdose administration errors. | Add full-text review in a later run if accessible. |
| B6 | [Poison-center experience with GLP-1 exposures](https://pmc.ncbi.nlm.nih.gov/articles/PMC11288212/) | B | Medication errors | 2026-07-14 | Reports pen-use misunderstanding as a meaningful share of exposures; semaglutide was the most frequent exposure in that center’s dataset. | Broader GLP-1 evidence; not specific to click-counting. |
| B7 | [American Diabetes Association journal report: GLP-1 shortage strategies](https://diabetesjournals.org/clinical/article/41/3/467/148676/Special-Report-Potential-Strategies-for-Addressing) | B | Clinical practice / shortage | 2026-07-14 | Publishes a 74-click full-scale table across U.S. 2/3, 4/3, and 8/3 mg/mL pen configurations. For the 4 mg/3 mL pen: 9 ≈ 0.12 mg, 18 ≈ 0.25 mg, 37 ≈ 0.5 mg, 49 ≈ 0.66 mg, 59 ≈ 0.8 mg, 74 ≈ 1 mg. Says values are mathematically calculated, not manufacturer-confirmed, and warns of high confusion/error potential. | Strongest U.S. professional source. Same click number maps to different mg by pen; 2024 erratum did not change the table. |
| B8 | [BC Diabetes: Semaglutide for weight loss and diabetes control](https://www.bcdiabetes.ca/wp-content/uploads/bcdpdfs/Semaglutide-for-weight-loss-and-diabetes-control.pdf) | B | Clinical practice / cost / brand variation | 2026-07-14 | Current clinician handout states Ozempic-branded 4 mg pen requires 72 clicks for 1 mg, gives 9/18/27/36/72 mappings, and states apo-semaglutide 4 mg pen requires 75 clicks for 1 mg. | Corroborates real use and brand-specific variation but conflicts with ADA’s 74-click scale. Canadian context. |
| B9 | [Erratum to ADA shortage report](https://pmc.ncbi.nlm.nih.gov/articles/PMC11486853/) | B | Source QA | 2026-07-14 | Corrects liraglutide frequency in a different table; does not alter the semaglutide click table. | Checked so the deck can cite the original table with confidence about the published correction. |
| C1 | [The Atlantic: “Why People Are Breaking Open Their Mounjaro Pens”](https://www.theatlantic.com/health/archive/2024/08/ozempic-hackers/679464/) | C | Journalism / viral practice | 2026-07-14 | Reports dose-splitting and pen-hacking driven by price, insurance loss, side effects, and fixed-dose design; quotes Novo condemning tampering and clinicians describing flexible titration. | Best narrative source for economics + desperation + clinician ambivalence. |
| D1 | [FormBlends click chart](https://formblends.com/articles/glp1-hub/ozempic-click-chart) | D | SEO / calculator ecosystem | 2026-07-14 | Repeats 18/36 across unlike pen configurations and reports 74/150 for a 2-mg-dose configuration, conflicting with the ADA concentration-specific table. | Treat as a viral artifact, not validation. It demonstrates cross-pen copying and unsupported precision. |
| D2 | [GLPCalc click calculator](https://glpcalc.com/ozempic-clicks) | D | Calculator ecosystem | 2026-07-14 | Shows competing mappings for 2 mg total, 4 mg total, and 8 mg total pens; emphasizes concentration differences. | Useful for documenting how users are taught to convert clicks; verify all numbers independently. |
| D3 | [Reddit r/Ozempic discussion: “Pens & Clicks”](https://www.reddit.com/r/Ozempic/comments/waf8iq) | D | User-generated | 2026-07-14 | Shows users correcting one another about which chart applies to which pen; reports 36 clicks as 0.5 mg on one configuration and 1 mg on a higher-concentration configuration. | Good evidence of confusion and peer-to-peer harm reduction; anecdotes only. |
| D4 | [Reddit r/Ozempic: 1-mg pen click discussion](https://www.reddit.com/r/Ozempic/comments/1h8aq33) | D | User-generated | 2026-07-14 | Conflicting comments report 72, 74, or 36 clicks depending on pen interpretation. | Strong example of instability in online knowledge; do not quote as dosage guidance. |
| D5 | [Reddit r/Ozempic: TikTok and 4-mg-pen click discussion](https://www.reddit.com/r/Ozempic/comments/1paikxk) | D | User-generated / viral | 2026-07-14 | Users explicitly report seeing TikTok-based click dosing and using a 4-mg pen with click charts; comments show confusion over leftover medication and discard timing. | Direct evidence of cross-platform migration; no reliable view-count data obtained. |
| D6 | [ClickDose calculator](https://clickdose.io/en/ozempic-click-counter.html) | D | Calculator ecosystem | 2026-07-14 | Claims all strengths deliver a fixed 0.01 mg per click. | Conflicts with concentration-based calculations and should be treated as an example of misinformation/oversimplification. |

## Search lanes completed

1. FDA/DailyMed/Novo labeling and instructions.
2. Manufacturer medical-information position on click-counting.
3. Health-system and professional medication-safety guidance.
4. Published poison-control and overdose-error evidence.
5. Journalism on pen hacking and dose splitting.
6. SEO click charts/calculators.
7. Reddit discussions showing peer correction, chart drift, and nomenclature confusion.
8. Independent unit, rounding, proportional-scale, one-click-sensitivity, and 56-day utilization calculations.
9. Current Canadian and European presentation variants and marked-dose ambiguity.

## Search lanes still open for the next run

- TikTok/Instagram/YouTube posts and hashtags; archive dates, view counts, and recurring claims rather than relying on search snippets.
- Pharmacist-authored charts with named authors, publication dates, and institutional affiliation.
- Exact product codes and device-generation histories for additional non-U.S. and generic presentations.
- FDA FAERS or poison-center trend data specific to branded Ozempic pen errors rather than compounded vials.
- Ozempic-specific bench testing of expelled mass/volume at unmarked settings across devices and lots; no validation study was located.
- Clinician interviews or published obesity-medicine guidance on intermediate titration.
- Pricing, insurance, shortage, and access evidence motivating dose-splitting.

## New findings from 2026-07-14 follow-up pass

- Search results surfaced a peer-reviewed poison-center study in which pen-use misunderstanding was a notable category of GLP-1 exposure error; this broadens the safety lane beyond compounded vials, but it does not identify click-counting as the cause.
- Search results surfaced a PubMed-indexed case series specifically about semaglutide administration-error overdoses; full-text review remains open.
- TikTok-specific web indexing is poor, but Reddit users explicitly describe seeing TikTok click-dosing posts and then searching for charts. This supports a cross-platform spread claim, not a prevalence claim.
- A calculator site claims a fixed 0.01 mg per click across all pen strengths. That conflicts with the FDA-listed concentrations and is a useful example of why online calculators need source auditing.
- The quantitative audit found that the prior memo’s 2-mg-total and 8-mg-total examples had copied 4-mg-pen click values across concentrations. Those examples were removed and replaced with the ADA report’s configuration-specific proportional table.
- The BC Children’s handout contains an internal unit mismatch: “1 click = 0.01 mg” cannot mathematically coexist with “72 clicks = 1 mg.”
- Current Canadian and European product documents show that total content plus volume may still be insufficient to identify a pen’s marked dose.
- The 72-versus-74 source split implies about a 2.7–2.8% proportional difference, but no measured uncertainty or unmarked-dose accuracy data were located.
- Whole-click rounding is a separate layer: 0.25 × 74 = 18.5 clicks, while the ADA table prints 18 without stating a general tie-breaking rule. Several displayed dose values are rounded from the proportional result.
- Fifty-six days equals eight elapsed weekly intervals, but inclusive date listing can show nine dates from day 0 through day 56. The ADA table uses an eight-dose convention; disposal-date instructions govern rather than simple event counting.

## Focused 4 mg-pen note

- The U.S. 4 mg/3 mL pen is officially a 1 mg-dose pen: 4 mg total, 1.34 mg/mL, four marked 1 mg injections.
- Credible unofficial sources publish 18 clicks for approximately 0.25 mg, 36 or 37 for approximately 0.5 mg, and 72 or 74 for approximately 1 mg on this configuration.
- The 72–74 notation is source disagreement, not a confidence interval, device tolerance, or validated range.
- The BC Children’s handout’s “1 click = 0.01 mg” line is incompatible with its own 72-click-to-1-mg table.
- Under linear source-scale assumptions, the 72-versus-74 difference is about 2.7–2.8%; one click is roughly 5.4–5.6% of a 0.25-mg target.
- Whole-click rounding and rounded displayed dose labels must be distinguished from source disagreement and measured device error.
- Printed concentration and volume figures are rounded: they cannot establish exact drug per click, and Novo declines to provide that value.
- The ADA table applies an eight-dose convention to the 56-day/8-week in-use limit; calendar endpoint counting must not be treated as permission for an additional dose. Low-dose use can leave nominal drug unused.
- No source located establishes a universally validated click count for every 4 mg/3 mL pen. Novo explicitly declines to provide one.
- The final pass found two credible but conflicting unofficial mappings: BC Diabetes uses 36/72 clicks for 0.5/1 mg, while the ADA journal report calculates 37/74. Both use 18 for 0.25 mg.

## Known unresolved conflicts

- Sources disagree about whether click counts should be 72, 74, or—for a different brand—75 for a full 1-mg setting. The difference may reflect device, brand, market, counting convention, dial direction, or error; no source establishes a universal count.
- Some SEO pages claim click counts are “confirmed in clinical use” while also acknowledging Novo does not validate them. No clinical validation study has been located.
- “2 mg pen” and “4 mg pen” are used inconsistently online to mean total cartridge strength, per-dose marking, or an international product. Country, brand, total volume, concentration, marked dose, product code, and date should be captured for every claim.